Abstract
Melanoma is characterised by its ability to metastasise at early stages of tumour development. Current clinico-pathologic staging based on the American Joint Committee on Cancer criteria is used to guide surveillance and management in early-stage disease, but its ability to predict clinical outcome has limitations. Herein we review the genomics of melanoma subtypes including cutaneous, acral, uveal and mucosal, with a focus on the prognostic and predictive significance of key molecular aberrations. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
Author supplied keywords
Cite
CITATION STYLE
Rabbie, R., Ferguson, P., Molina-Aguilar, C., Adams, D. J., & Robles-Espinoza, C. D. (2019, April 1). Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. Journal of Pathology. John Wiley and Sons Ltd. https://doi.org/10.1002/path.5213
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.